Daniel Hume, 59, has served as a member of our Board since June 2015. Mr. Hume is currently a managing partner at Kirby McInerney, LLP. Mr. Hume s law practice focuses on securities law regulation, structured finance, antitrust, and civil litigation. Mr. Hume is member of the board of directors of for Lirum Therapeutics, a private biopharmaceutical company, and Insight Digital Partners II (DYOR), which is a SPAC focused on merging with high-growth sectors of the digital economy. Mr. Hume was recently a member of the boards of directors of Stemline Therapeutics Inc. (Nasdaq: STML), a late clinical stage biopharmaceutical company, and National Holdings Corporation (Nasdaq: NHLD), a financial services company, until those companies successful acquisitions. Mr. Hume is admitted to the New York State Bar and federal courts around the country, including the United States Supreme Court. Mr. Hume received a B.A. in philosophy and graduated magna cum laude from the State University of New York at Albany, and earned a J.D. from the Columbia University Law School, where he served as Notes Editor for the Columbia Journal of Environmental Law. We believe that Mr. Hume is qualified to serve on our Board due to his substantial financial and legal experience as well as his experience on several other boards, some within the pharmaceutical industry.